Upper Macungie grants final land development approval for Lilly's Fogelsville plant

Upper Macungie Township's board of supervisors voted unanimously on September 2, 2026, to approve the Final Land Development Plan and Sewage Planning Module for Eli Lilly's manufacturing facility in Fogelsville, Pennsylvania ^[1]. The approval came with a binding condition: the construction traffic study presented at the meeting must be built into later development documents, making its mitigation steps enforceable if problems arise ^[1].

Lilly's director of entitlements and permitting told the board that peak construction is expected from the fourth quarter of 2027 through the first quarter of 2029, when as many as 1,500 workers — about 1,200 trade workers and 300 administrative staff — could be on site at once ^[1]. To manage that traffic, Lilly has secured 600 off-site parking spaces in the Tilghman Street area, identified more parking in the nearby Windsor office area, and plans a shuttle system linking those lots to five site entrances ^[1]. The company also plans to install a new traffic signal and widen Main Street in 2027, ahead of peak construction ^[1].

The project has been described elsewhere as a $3.5 billion investment, the largest life sciences project in Pennsylvania's history, tied to Lilly's broader $50 billion U.S. manufacturing expansion announced since 2020 ^[2]. That earlier account said the plant would focus on "next-generation weight-loss treatments," including retatrutide, an investigational triple hormone receptor agonist still in clinical trials — not yet an approved medicine ^[2]. It also cited roughly 850 permanent jobs, about 2,000 construction workers, a $100 million state incentive package, and a target of full operation by 2031 ^[2]. That construction-worker figure is notably higher than the up-to-1,500 figure Lilly gave the township board in September 2026, and the sources do not explain the difference ^[1][2].

Other business at the September 2 meeting was unrelated to Lilly: supervisors approved using PA SITES state funding for a new sewer trunk line to serve a former Keurig Dr Pepper facility that Chobani plans to take over, capped at 800,000 gallons of wastewater per day ^[1]. The board also welcomed newly appointed Supervisor Andrew Snyder and elected Sunny Ghai as vice chairman ^[1].

Why it matters for patients

This approval is a local zoning and infrastructure milestone, not a change in drug supply or pricing today. Nothing in the sources suggests the Fogelsville plant will affect current availability of Zepbound, Mounjaro, Ozempic, Wegovy, or Rybelsus in the near term. If the plant is built out as described, it could eventually add U.S. manufacturing capacity for GLP-1-class medicines, which industry watchers have linked to efforts to secure domestic supply chains and reduce shortages ^[2]. But peak construction alone runs into 2029, and one source projects the facility would not be fully operational until 2031 ^[1][2].

Patients should also note that one source ties the plant to retatrutide, a triple hormone receptor agonist that is still investigational and has not been approved by the FDA ^[2]. That is different from currently marketed GLP-1 drugs, and its future availability is not established by anything in these sources.

What happens next

Lilly plans to install a traffic signal and widen Main Street in 2027, before peak construction begins ^[1]. Peak construction, with up to 1,500 workers on site, is expected from the fourth quarter of 2027 through the first quarter of 2029 ^[1]. One earlier report projected the facility would be fully operational by 2031 ^[2]. The traffic mitigation plan approved on September 2 is now a binding condition of the project, meaning the township can require continued coordination with Lilly if traffic problems emerge during construction ^[1].